Health Canada reasonable in finding Natco’s indirect comparison to GENVOYA triggered data protection

Published date30 August 2020
Subject MatterAbbreviated New Drug Submission (ANDS),Marketing Exclusivity Periods,Pharmaceutical Patents,Data Protection,Generic Drugs,Health Canada,Dismissals,Judicial Review,Food and Drug Administrations,Canada,Patent Infringement
AuthorKatie Lee
Law FirmSmart & Biggar

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT